Bromide

Bromide

SCHEMBL5551014

Br.CCCCCCCCCCCC(CCCCl)N1CCCC1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A4 known ✓ P31645 1/20 0.30
SLC6A3 known ✓ Q01959 1/20 0.30
TSHR P16473 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.34
FDPS P14324 3/20 0.32
HRH3 Q9Y5N1 2/20 0.32
MAPT P10636 2/20 0.32
LTA4H P09960 1/20 0.32
LMNA P02545 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
MAPK1 P28482 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
DNM1 Q05193 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5547799 0.98 TSHR (0.40) TSHRALDH1A1TDP1FDPSHRH3
Bromide SCHEMBL5550542 0.98 TSHR (0.40) TSHRALDH1A1TDP1FDPSHRH3
Bromide SCHEMBL8346769 0.89 HRH3 (0.43) HRH3LTA4H
SCHEMBL19441034 0.89 FDPS (0.39) TSHRTDP1FDPSHRH3MAPT
SCHEMBL14127423 0.89 FDPS (0.39) TSHRTDP1FDPSHRH3MAPT
SCHEMBL23251113 0.89 FDPS (0.39) TSHRTDP1FDPSHRH3MAPT
SCHEMBL2228223 0.89 FDPS (0.39) TSHRTDP1FDPSHRH3MAPT
SCHEMBL14636358 0.89 FDPS (0.39) TSHRTDP1FDPSHRH3MAPT
SCHEMBL2012868 0.89 FDPS (0.39) TSHRTDP1FDPSHRH3MAPT
SCHEMBL12469943 0.89 FDPS (0.39) TSHRTDP1FDPSHRH3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070190021-A1 Poly(diallylamine)-based bile acid sequestrants HOLMES-FARLEY STEPHEN R 2007-08-16 US disclosed
US-7125547-B2 Poly(diallylamine)-based bile acid sequestrants GENZYME CORPORATION (US) 2006-10-24 US disclosed
US-20040151687-A1 Poly(diallylamine)-based bile acid sequestrants GENZYME CORPORATION 2004-08-05 US disclosed
US-6726905-B1 LOWERING SERUM PHOSPHATE GENZYME CORPORATION 2004-04-27 US disclosed
US-6610283-B1 Method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a GENZYME CORPORATION 2003-08-26 US disclosed
US-6203785-B1 ADMINISTERING CROSSLINKED CATIONIC POLYMER ANTICHOLESTEROL AGENTS GELTEX PHARMACEUTICALS, INC. 2001-03-20 US disclosed
WO-1999022743-A1 POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS GELTEX PHARMACEUTICALS, INC. (US) 1999-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070190021-A1 Poly(diallylamine)-based bile acid sequestrants NR1H4, SLC10A2, SLC10A1 SLC6A4 386/4885SLC6A3 581/4885TSHR 4075/4885
US-20040151687-A1 Poly(diallylamine)-based bile acid sequestrants NR1H4, SLC10A2, SLC10A1 SLC6A4 1411/4885SLC6A3 691/4885TSHR 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.